BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1196 related articles for article (PubMed ID: 17161777)

  • 21. The renin-angiotensin-aldosterone system and fibrinolysis.
    Felmeden DC; Lip GY
    J Renin Angiotensin Aldosterone Syst; 2000 Sep; 1(3):240-4. PubMed ID: 11881031
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fixed-dose combinations of renin-angiotensin blocking agents with calcium channel blockers or hydrochlorothiazide in the treatment of hypertension.
    Bramlage P
    Expert Opin Pharmacother; 2009 Aug; 10(11):1755-67. PubMed ID: 19538001
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension.
    Fogari R; Zoppi A; Salvadeo SA; Mugellini A; Lazzari P; Santoro T; Derosa G
    Hypertens Res; 2011 Apr; 34(4):509-15. PubMed ID: 21179101
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Hypertension combination therapy with renin-angiotensin system blockers].
    Soucek M
    Vnitr Lek; 2009 Sep; 55(9):719-23. PubMed ID: 19785368
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fibrinolytic balance, the renin-angiotensin system and atherosclerotic disease.
    Vaughan DE
    Eur Heart J; 1998 Jul; 19 Suppl G():G9-12. PubMed ID: 9717049
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine.
    Ferri C; Croce G; Desideri G
    Adv Ther; 2008 Apr; 25(4):300-20. PubMed ID: 18449492
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nephroprotection by antihypertensive agents.
    Schmieder RE
    J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S55-64. PubMed ID: 7898095
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of renin-angiotensin to calcium channel blockade in renal disease.
    Tikkanen I; Johnston CI
    Kidney Int Suppl; 1997 Dec; 63():S19-22. PubMed ID: 9407414
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A; Teo KK
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RAS inhibition in hypertension.
    Ibrahim MM
    J Hum Hypertens; 2006 Feb; 20(2):101-8. PubMed ID: 16397519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine?
    Burnier M; Pruijm M; Wuerzner G
    Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):981-7. PubMed ID: 19619074
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of the renin--angiotensin system on the vessel wall: using ACE inhibition to improve endothelial function.
    Neutel JM
    J Hum Hypertens; 2004 Sep; 18(9):599-606. PubMed ID: 15190263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Hypertension 2007-2008].
    Chatzikyrkou C; Menne J; Haller H
    Med Klin (Munich); 2009 Aug; 104(8):614-21. PubMed ID: 19701732
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combining RAAS and calcium channel blockade: ACCOMPLISH in perspective.
    Kjeldsen SE; Weber M; Oparil S; Jamerson KA
    Blood Press; 2008; 17(5-6):260-9. PubMed ID: 19061055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacogenetics of antihypertensive treatment.
    Arnett DK; Claas SA; Glasser SP
    Vascul Pharmacol; 2006 Feb; 44(2):107-18. PubMed ID: 16356784
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pharmacological hypertension therapy].
    Pedersen OL; Christensen KL; Bang LE; Ibsen H; Schultz-Larsen P
    Ugeskr Laeger; 2009 Jun; 171(24):2022-5. PubMed ID: 19523367
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of angiotensin-converting enzyme inhibitors in vascular modulation: beyond the hypertensive effects.
    Katragadda S; Arora RR
    Am J Ther; 2010; 17(1):e11-23. PubMed ID: 20090429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short-term effects of angiotensin receptor blockers on blood pressure control, and plasma inflammatory and fibrinolytic parameters in patients taking angiotensin-converting enzyme inhibitors.
    Agirbasli M; Cincin A; Baykan OA
    J Renin Angiotensin Aldosterone Syst; 2008 Mar; 9(1):22-6. PubMed ID: 18404606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced risk of thromboembolic disease in hypertension from platelet hyperfunction and decreased fibrinolytic activity: has antihypertensive therapy any influence?
    Winther K; Gleerup G; Hedner T
    J Cardiovasc Pharmacol; 1992; 19 Suppl 3():S21-4. PubMed ID: 1376829
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current status of antihypertensive prescription and associated blood pressure control in Japan.
    Mori H; Ukai H; Yamamoto H; Saitou S; Hirao K; Yamauchi M; Umemura S
    Hypertens Res; 2006 Mar; 29(3):143-51. PubMed ID: 16755149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 60.